Eyenovia, Inc. (EYEN)

NASDAQ: EYEN · IEX Real-Time Price · USD
3.21
+0.01 (0.31%)
Mar 30, 2023, 1:28 PM EDT - Market open
0.31%
Market Cap 115.59M
Revenue (ttm) 10.00M
Net Income (ttm) -18.90M
Shares Out 36.12M
EPS (ttm) -0.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 125,816
Open 3.25
Previous Close 3.20
Day's Range 3.15 - 3.29
52-Week Range 1.50 - 3.34
Beta 1.66
Analysts Buy
Price Target 14.62 (+355.45%)
Earnings Date May 10, 2023

About EYEN

Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydria... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 25, 2018
Employees 43
Stock Exchange NASDAQ
Ticker Symbol EYEN
Full Company Profile

Financial Performance

In 2021, Eyenovia's revenue was $14.00 million, an increase of 600.00% compared to the previous year's $2.00 million. Losses were -$12.78 million, -35.36% less than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for EYEN stock is "Buy." The 12-month stock price forecast is $14.62, which is an increase of 355.45% from the latest price.

Price Target
$14.62
(355.45% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30

Company to host an investor conference call and webcast at 4:30 pm ET Company to host an investor conference call and webcast at 4:30 pm ET

1 week ago - GlobeNewsWire

Eyenovia Announces Independent Director Stephen Benjamin to Step Down to Assume Role of Head of White House's Office of Public Engagement

NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its ow...

1 month ago - GlobeNewsWire

Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals

Collaboration will combine Eyenovia's Optejet® dispensing technology with Formosa's APNT™ nanoparticle formulation platform for the potential development of new topical therapeutics in high-value opht...

1 month ago - GlobeNewsWire

Formosa Pharmaceuticals Announces Development Collaboration Agreement with Eyenovia

The collaboration will combine Formosa's proprietary APNT™ nanoparticle formulation platform with Eyenovia's Optejet® dispensing technology for the development of new ophthalmic therapies in high-valu...

1 month ago - PRNewsWire

Eyenovia Reveals Positive Evidence That Optejet® Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Drops

Academic study found the Optejet® to be comparable to non-preserved drops in lessening the proinflammatory response Academic study found the Optejet® to be comparable to non-preserved drops in lesseni...

2 months ago - GlobeNewsWire

Eyenovia Announces Participation at the 2023 International Consumer Electronics Show

Booth to feature “smart” remote patient monitoring capabilities being developed for future versions of the company's novel Optejet® drug delivery technology

3 months ago - GlobeNewsWire

Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation

Agency assigns PDUFA action date of May 8, 2023

3 months ago - GlobeNewsWire

Eyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President

Company also announces that Julia Haller, MD, is stepping down from its Board of Directors Company also announces that Julia Haller, MD, is stepping down from its Board of Directors

4 months ago - GlobeNewsWire

Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund

Transaction proceeds, together with cash on-hand, expected to fund operations through late 2023/early 2024, including potential FDA approval of MydCombi™ Transaction proceeds, together with cash on-ha...

4 months ago - GlobeNewsWire

Eyenovia to Present at Upcoming BTIG Ophthalmology Day

NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its o...

4 months ago - GlobeNewsWire

Eyenovia Reports Third Quarter 2022 Financial Results and Provides Business Update

Announced positive results from the second Phase 3 study of MicroLine in presbyopia, VISION-2; Company planning to meet with the FDA to gain alignment on regulatory path forward as a drug/device combi...

4 months ago - GlobeNewsWire

Eyenovia to Report Third Quarter 2022 Results on Thursday, November 10

Company to host an investor conference call and webcast at 4:30pm ET on that day Company to host an investor conference call and webcast at 4:30pm ET on that day

5 months ago - GlobeNewsWire

Eyenovia to Present at the American Academy of Optometry's Annual Meeting

NEW YORK, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its o...

5 months ago - GlobeNewsWire

Eyenovia Announces Positive Results from VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopia

NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its o...

5 months ago - GlobeNewsWire

Eyenovia Announces Planned Retirement of Lead Independent Director Ken Lee, Jr.

NEW YORK, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its ...

6 months ago - GlobeNewsWire

Eyenovia to Present at Upcoming Healthcare Conferences

NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array ...

7 months ago - GlobeNewsWire

Eyenovia to Participate in Multiple Medical Meetings in September

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutic...

7 months ago - GlobeNewsWire

Eyenovia Reports Second Quarter 2022 Financial Results

Announced appointment of Michael Rowe as Chief Executive Officer and Board member

8 months ago - GlobeNewsWire

Eyenovia to Report Second Quarter 2022 Results on Wednesday, August 10

Company to host an investor conference call and webcast at 4:30pm ET on that day Company to host an investor conference call and webcast at 4:30pm ET on that day

8 months ago - GlobeNewsWire

Eyenovia Announces Appointment of Ophthalmic Industry Veteran Michael Rowe as Chief Executive Officer and Board Member

Appointment of Mr. Rowe, Eyenovia's current Chief Operating Officer, maintains continuity while bringing significant ophthalmic industry, operations and commercialization expertise to the CEO role App...

8 months ago - GlobeNewsWire

Eyenovia Provides Manufacturing Update and Announces Appointment of Bren Kern as SVP of Manufacturing and Operations

New internal manufacturing capabilities to complement existing contract manufacturing relationships New internal manufacturing capabilities to complement existing contract manufacturing relationships

9 months ago - GlobeNewsWire

Eyenovia Announces Appointments of Dr. Ellen Strahlman and Dr. Ram Palanki as New and Independent Members of its Board of Directors

NEW YORK, July 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics...

9 months ago - GlobeNewsWire

Eyenovia Strategic Partner Arctic Vision Enrolls First Patient in Phase III Clinical Trial of ARVN003 (MicroLine) for Presbyopia in China

Arctic Vision also licensed and is developing Eyenovia's programs for pediatric progressive myopia (MicroPine) and pharmacologic mydriasis (MydCombi™) in Greater China and South Korea Arctic Vision al...

9 months ago - GlobeNewsWire

UPDATE: Eyenovia Announces Virtual 2022 Annual Meeting of Stockholders

NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) investigational product...

10 months ago - GlobeNewsWire

Eyenovia Announces Virtual 2022 Annual Meeting of Stockholders

NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) investigational product...

10 months ago - GlobeNewsWire